Tech Company Financing Transactions

Clinipace Funding Round

Private investors participated in a $5.7 million funding round for Clinipace. The round closed on 9/11/2018.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Proceeds Purpose
Proceeds purposes were not disclosed. 13 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.

Company Information

Company Status
Private & Independent
Mailing Address
3800 Paramount Pkwy. 100
Morrisville, NC 27560
Email Address
As a digital CRO (dCRO), Clinipace pioneered an innovative service model to transform drug and medical device development by delivering technology-amplified services to improve performance, collaboration, and visibility across all stakeholders.
Clinipace LinkedIn Company Profile
Social Media
Clinipace Company Twitter Account
Company News
Clinipace News
Clinipace on Facebook
Clinipace on YouTube

Management Team

Email & Social
Chief Executive Officer
Jason Monteleone
  Jason Monteleone LinkedIn Profile  Jason Monteleone Twitter Account  Jason Monteleone News  Jason Monteleone on Facebook
Chief Financial Officer
Karen Turner
  Karen Turner LinkedIn Profile  Karen Turner Twitter Account  Karen Turner News  Karen Turner on Facebook
Chief Information Officer
Michael Townley
  Michael Townley LinkedIn Profile  Michael Townley Twitter Account  Michael Townley News  Michael Townley on Facebook
Chief Medical Officer
Sharon Moore
  Sharon Moore LinkedIn Profile  Sharon Moore Twitter Account  Sharon Moore News  Sharon Moore on Facebook
Chief Operating Officer
Susan Acker-Walsh
  Susan Acker-Walsh LinkedIn Profile  Susan Acker-Walsh Twitter Account  Susan Acker-Walsh News  Susan Acker-Walsh on Facebook
Vice President
Charlene Dark
  Charlene Dark LinkedIn Profile  Charlene Dark Twitter Account  Charlene Dark News  Charlene Dark on Facebook
Vice President
Brian Travers
  Brian Travers LinkedIn Profile  Brian Travers Twitter Account  Brian Travers News  Brian Travers on Facebook
VP - Bus. Development
John Cargill
  John Cargill LinkedIn Profile  John Cargill Twitter Account  John Cargill News  John Cargill on Facebook
VP - Bus. Development
Dawn Sauro
  Dawn Sauro LinkedIn Profile  Dawn Sauro Twitter Account  Dawn Sauro News  Dawn Sauro on Facebook
VP - General Counsel
Parker Honeycutt
  Parker Honeycutt LinkedIn Profile  Parker Honeycutt Twitter Account  Parker Honeycutt News  Parker Honeycutt on Facebook
VP - Human Resources
Judith Barnett
  Judith Barnett LinkedIn Profile  Judith Barnett Twitter Account  Judith Barnett News  Judith Barnett on Facebook
VP - Operations
Ian Fraser
  Ian Fraser LinkedIn Profile  Ian Fraser Twitter Account  Ian Fraser News  Ian Fraser on Facebook
VP - Operations
Cindy Venendaal
  Cindy Venendaal LinkedIn Profile  Cindy Venendaal Twitter Account  Cindy Venendaal News  Cindy Venendaal on Facebook
VP - Regulatory Affairs
Nikolas Burlew
  Nikolas Burlew LinkedIn Profile  Nikolas Burlew Twitter Account  Nikolas Burlew News  Nikolas Burlew on Facebook
VP - Regulatory Affairs
Marie Hanley
  Marie Hanley LinkedIn Profile  Marie Hanley Twitter Account  Marie Hanley News  Marie Hanley on Facebook



Browse more venture capital transactions:

Prev: 9/11/2018: Atrium LTS venture capital transaction
Next: 9/11/2018: Jump Technologies venture capital transaction


Share this article


Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary